Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464155 | 0.94 | TAAR1 (0.40) | NFE2L2PDE4BRORCTAAR1CYP3A4 | |
| SCHEMBL4460448 | 0.92 | CYP3A4 (0.44) | NFE2L2TAAR1CYP3A4PTGS1PTGS2 | |
| SCHEMBL4456792 | 0.92 | CYP3A4 (0.44) | NFE2L2PDE4BRORCCYP3A4KCNA5 | |
| SCHEMBL4460584 | 0.90 | TAAR1 (0.44) | TAAR1KCNA5PTGS2 | |
| SCHEMBL4457222 | 0.89 | TAAR1 (0.43) | TAAR1KCNA5PTGS2 | |
| SCHEMBL4472068 | 0.87 | TAAR1 (0.39) | PDE4BTAAR1CYP3A4KCNA5PTGS1 | |
| SCHEMBL4461909 | 0.87 | TAAR1 (0.39) | PDE4BTAAR1CYP3A4PTGS1PTGS2 | |
| SCHEMBL4472149 | 0.87 | TAAR1 (0.41) | TAAR1KCNA5PTGS2 | |
| SCHEMBL4453068 | 0.85 | TAAR1 (0.39) | TAAR1CYP3A4KCNA5PTGS1PTGS2 | |
| SCHEMBL4472842 | 0.85 | TAAR1 (0.40) | PDE4BTAAR1CYP3A4KCNA5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | NFE2L2 3320/4885PDE4B 2272/4885RORC 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.